Literature DB >> 22705279

The metabolic basis of kidney cancer.

W Marston Linehan1, Christopher J Ricketts.   

Abstract

Kidney cancer is not a single disease; it is made up of a number of different types of cancer that occur in the kidney. Each of these different types of kidney cancer can have a different histology, have a different clinical course, can respond differently to therapy and is caused by a different gene. Kidney cancer is essentially a metabolic disease; each of the known genes for kidney cancer, VHL, MET, FLCN, TSC1, TSC2, TFE3, TFEB, MITF, fumarate hydratase (FH), succinate dehydrogenase B (SDHB), succinate dehydrogenase D (SDHD), and PTEN genes is involved in the cells ability to sense oxygen, iron, nutrients or energy. Understanding the metabolic basis of kidney cancer will hopefully provide the foundation for the development of effective forms of therapy for this disease. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22705279      PMCID: PMC3563773          DOI: 10.1016/j.semcancer.2012.06.002

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  92 in total

1.  Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3.

Authors:  S Hosoe; H Brauch; F Latif; G Glenn; L Daniel; S Bale; P Choyke; M Gorin; E Oldfield; A Berman
Journal:  Genomics       Date:  1990-12       Impact factor: 5.736

2.  Identification of the von Hippel-Lindau disease tumor suppressor gene.

Authors:  F Latif; K Tory; J Gnarra; M Yao; F M Duh; M L Orcutt; T Stackhouse; I Kuzmin; W Modi; L Geil
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

3.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.

Authors:  Hartmut P H Neumann; Christian Pawlu; Mariola Peczkowska; Birke Bausch; Sarah R McWhinney; Mihaela Muresan; Mary Buchta; Gerlind Franke; Joachim Klisch; Thorsten A Bley; Stefan Hoegerle; Carsten C Boedeker; Giuseppe Opocher; Jörg Schipper; Andrzej Januszewicz; Charis Eng
Journal:  JAMA       Date:  2004-08-25       Impact factor: 56.272

4.  Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons.

Authors:  A R Birt; G R Hogg; W J Dubé
Journal:  Arch Dermatol       Date:  1977-12

Review 5.  Hereditary papillary renal cell carcinoma.

Authors:  B Zbar; K Tory; M Merino; L Schmidt; G Glenn; P Choyke; M M Walther; M Lerman; W M Linehan
Journal:  J Urol       Date:  1994-03       Impact factor: 7.450

Review 6.  Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes.

Authors:  James Brugarolas; William G Kaelin
Journal:  Cancer Cell       Date:  2004-07       Impact factor: 31.743

7.  The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease.

Authors:  Branden G Duffey; Peter L Choyke; Gladys Glenn; Robert L Grubb; David Venzon; W Marston Linehan; McClellan M Walther
Journal:  J Urol       Date:  2004-07       Impact factor: 7.450

8.  Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene.

Authors:  Laura S Schmidt; Michael L Nickerson; Debora Angeloni; Gladys M Glenn; McClellan M Walther; Paul S Albert; Michelle B Warren; Peter L Choyke; Carlos A Torres-Cabala; Maria J Merino; Joan Brunet; Victòria Bérez; Joan Borràs; Giovanni Sesia; Lindsay Middelton; John L Phillips; Catherine Stolle; Berton Zbar; Stephen E Pautler; W Marston Linehan
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

9.  Central nervous system involvement in Von Hippel-Lindau disease.

Authors:  M R Filling-Katz; P L Choyke; E Oldfield; L Charnas; N J Patronas; G M Glenn; M B Gorin; J K Morgan; W M Linehan; B R Seizinger
Journal:  Neurology       Date:  1991-01       Impact factor: 9.910

10.  Endolymphatic sac tumors in von Hippel-Lindau disease.

Authors:  Daniel Choo; Lawrence Shotland; Maryann Mastroianni; Gladys Glenn; Carter van Waes; W Marston Linehan; Edward H Oldfield
Journal:  J Neurosurg       Date:  2004-03       Impact factor: 5.115

View more
  56 in total

1.  Comparison of PD-L1 Scores in Primary Kidney Tumors Versus Accompanying Venous Tumor Thrombi: Retrospective, Comparative, Monocentric Study in Treatment-Naive Patients.

Authors:  Mehrdad Mazdak; Rieke Ringlstetter; Pouriya Faraj Tabrizi; Meryem Akkoyun; Mathias Wolters; Jessica Schmitz; Jan Hinrich Bräsen; Inga Peters; Markus Antonius Kuczyk; Hossein Tezval
Journal:  Adv Ther       Date:  2021-05-21       Impact factor: 3.845

2.  Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer.

Authors:  Brian Shuch; Nnenaya Agochukwu; Christopher J Ricketts; Cathy D Vocke; Rabindra Gautam; Maria Merino; W Marston Linehan; Ramaparasad Srinivasan
Journal:  J Clin Oncol       Date:  2014-07-14       Impact factor: 44.544

Review 3.  Pheochromocytoma: The First Metabolic Endocrine Cancer.

Authors:  Ivana Jochmanova; Karel Pacak
Journal:  Clin Cancer Res       Date:  2016-10-15       Impact factor: 12.531

Review 4.  Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.

Authors:  Vidhya Karivedu; Amit L Jain; Thomas J Eluvathingal; Abhinav Sidana
Journal:  Curr Urol Rep       Date:  2019-08-29       Impact factor: 3.092

5.  Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer.

Authors:  Daniel R Crooks; Nunziata Maio; Martin Lang; Christopher J Ricketts; Cathy D Vocke; Sandeep Gurram; Sevilay Turan; Yun-Young Kim; G Mariah Cawthon; Ferri Sohelian; Natalia De Val; Ruth M Pfeiffer; Parthav Jailwala; Mayank Tandon; Bao Tran; Teresa W-M Fan; Andrew N Lane; Thomas Ried; Darawalee Wangsa; Ashkan A Malayeri; Maria J Merino; Youfeng Yang; Jordan L Meier; Mark W Ball; Tracey A Rouault; Ramaprasad Srinivasan; W Marston Linehan
Journal:  Sci Signal       Date:  2021-01-05       Impact factor: 8.192

6.  Expression of sodium-dependent dicarboxylate transporter 1 (NaDC1/SLC13A2) in normal and neoplastic human kidney.

Authors:  Hyun-Wook Lee; Mary E Handlogten; Gunars Osis; William L Clapp; Dara N Wakefield; Jill W Verlander; I David Weiner
Journal:  Am J Physiol Renal Physiol       Date:  2016-12-07

Review 7.  Management of Atypical Renal Cell Carcinomas.

Authors:  Bobby C Liaw; Reza Mehrazin; Charles Baker; John P Sfakianos; Che-Kai Tsao
Journal:  Curr Treat Options Oncol       Date:  2017-09-14

Review 8.  The epigenetic landscape of renal cancer.

Authors:  Mark R Morris; Farida Latif
Journal:  Nat Rev Nephrol       Date:  2016-11-28       Impact factor: 28.314

Review 9.  Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets.

Authors:  Jamie D Weyandt; Craig B Thompson; Amato J Giaccia; W Kimryn Rathmell
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 10.  Recent developments in the treatment of renal cell carcinoma.

Authors:  Janice P Dutcher
Journal:  Ther Adv Urol       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.